GlpBio

Satraplatin

目录号: GC37593纯度: >99.50%同义词: 沙铂; BMS182751; BMY45594; JM216
An orally available antineoplastic platinum(IV) complex
Satraplatin
Cas No.: 129580-63-8
规格价格库存数量操作
1mg¥1,035.00现货
1
5mg¥2,520.00现货
1
10mg¥3,600.00现货
1
电话: 400-920-5774Email: sales@glpbio.cn

文献被引

本产品暂无引用记录;以下为 GlpBio 产品在 Nature / Cell / Science 等顶刊的客户引用样例
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

产品描述 Description

Satraplatin is an orally available antineoplastic platinum(IV) complex.1 It is more hydrophobic than cisplatin or oxaliplatin , which reduces transport-determined acquired resistance.1 Satraplatin also displays less neurotoxicity in rats than cisplatin or tetraplatin.2 Satraplatin has a favorable toxicity profile and appears to have clinical activity against a variety of malignancies.3

1.Kelland, L.R., Abel, G., McKeage, M.J., et al.Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): An orally active platinum drugCancer Res.53(11)2581-2586(1993) 2.McKeage, M.J., Boxall, F.E., Jones, M., et al.Lack of neurotoxicity of oral bisacetatoamminedichlorocyclohexylamine-platinum(IV) in comparison to cisplatin and tetraplatin in the ratCancer Res.54(3)629-631(1994) 3.Bhargava, A., and Vaishampayan, U.N.Satraplatin: Leading the new generation of oral platinum agentsExpert. Opin. Investig. Drugs18(11)1787-1797(2009)

实验参考方法 Experimental Reference Method

Cell experiment:

Cells are harvested, counted and distributed to microtiter plates in 100 μL medium at a density of 1×104 cells/well. Appropriate dilutions of test compounds (Satraplatin, etc.) are added to a total volume of 200 μL/well and plates incubated under tissue culture conditions for four days. Stock solutions of the compounds are prepared in either 70% ethanol or DMSO and diluted more than 100-fold for the assays. Solvent controls are included in all tests. Dose response curves are obtained by assessing cell proliferation at twofold drug dilutions in triplicate and used for calculation of IC50 values. Cell growth is quantified using a modified tetrazolium dye assay (MTT) and by measurement of the reduced formazane dye at 450 nm wavelength (medium control set to 100% proliferation)[1].

References:

[1]. Fiebiger W, et al. In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines. Clin Transl Oncol. 2011 Jan;13(1):43-9.
[2]. Yamano Y, et al. Antitumor activity of satraplatin in cisplatin-resistant oral squamous cell carcinoma cells. Head Neck. 2011 Mar;33(3):309-17.

产品文档 Product Documents

Purity:>99.50%

化学性质Chemical Properties

CAS 号
129580-63-8
同义词
沙铂; BMS182751; BMY45594; JM216
SMILES
[Cl-][Pt+4]([O-]C(C)=O)([O-]C(C)=O)([Cl-])([NH3])[NH2]C1CCCCC1
分子式
C10H22Cl2N2O4Pt
分子量
500.28 g/mol
溶解性
DMSO: ≥ 33 mg/mL (65.96 mM; DMSO can inactivate Satraplatin's activity)
保存条件
Store at -20°C
General tips
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
为了提高溶解度，请将管子加热至 37°C，然后在超声波浴中震荡一段时间。
Shipping Condition
评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备 RT，或根据请求配备蓝冰。

计算工具摩尔浓度 / 稀释 / 分子量 / 单位换算 / 体内配方 / 溶解度

g/mol